NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis $0.50 +0.04 (+8.40%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.48 -0.02 (-4.39%) As of 04/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LXRX alerts:Sign Up Key Stats Today's Range$0.43▼$0.5250-Day Range$0.29▼$0.9952-Week Range$0.28▼$2.45Volume16.82 million shsAverage Volume6.07 million shsMarket Capitalization$123.88 millionP/E RatioN/ADividend YieldN/APrice Target$3.67Consensus RatingHold Company OverviewLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Read More… Remove Ads Lexicon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreLXRX MarketRank™: Lexicon Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 339th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageLexicon Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lexicon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexicon Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.11% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently decreased by 17.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.11% of the float of Lexicon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently decreased by 17.28%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.58 News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest29 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 164% compared to the previous 30 days.MarketBeat Follows23 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 360% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexicon Pharmaceuticals' insider trading history. Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Stock News HeadlinesLexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2 at 8:00 AM | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC WainwrightMarch 30, 2025 | americanbankingnews.comCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.April 3, 2025 | Paradigm Press (Ad)Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Sell Rating from Analysts at StockNews.comMarch 29, 2025 | americanbankingnews.comLexicon stock soars on Novo Nordisk licensing dealMarch 29, 2025 | za.investing.comLexicon announces exclusive license agreement with Novo Nordisk for LX9851March 29, 2025 | markets.businessinsider.comLexicon announces exclusive license agreement with Novo Nordisk for LX9851March 29, 2025 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Lexicon PharmaceuticalsMarch 29, 2025 | benzinga.comSee More Headlines LXRX Stock Analysis - Frequently Asked Questions How have LXRX shares performed this year? Lexicon Pharmaceuticals' stock was trading at $0.7385 at the start of the year. Since then, LXRX stock has decreased by 31.9% and is now trading at $0.5031. View the best growth stocks for 2025 here. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Thursday, March, 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative trailing twelve-month return on equity of 107.38%. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA). Company Calendar Last Earnings3/06/2025Today4/02/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees140Year Founded1995Price Target and Rating Average Stock Price Target$3.67 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+628.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-177,120,000.00 Net Margins-4,109.41% Pretax Margin-4,138.33% Return on Equity-107.38% Return on Assets-64.09% Debt Debt-to-Equity Ratio0.56 Current Ratio7.45 Quick Ratio7.43 Sales & Book Value Annual Sales$31.08 million Price / Sales3.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.32Miscellaneous Outstanding Shares246,237,000Free Float229,493,000Market Cap$123.88 million OptionableOptionable Beta1.04 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:LXRX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.